Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers

Ikenna Madueke; Richard J Lee; David T Miyamoto

doi:10.1016/j.ucl.2022.09.010

Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers

Urol Clin North Am. 2023 Feb;50(1):109-114. doi: 10.1016/j.ucl.2022.09.010.

Authors

Ikenna Madueke¹, Richard J Lee², David T Miyamoto²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: icmadueke@mgh.harvard.edu.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

PMID: 36424075
DOI: 10.1016/j.ucl.2022.09.010

Abstract

Liquid biopsies such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have great potential to serve as prognostic and predictive biomarkers in urologic cancers. The possibility of using liquid biopsies for real-time noninvasive and dynamic monitoring of response to therapy has been an active area of investigation. In this brief review, we outline the evidence for the potential clinical utility of CTC and ctDNA analyses in prostate, urothelial, and renal cancers.

Keywords: Circulating tumor DNA; Circulating tumor cells; Genitourinary cancer.

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / genetics
Humans
Liquid Biopsy
Male
Neoplastic Cells, Circulating* / pathology
Urologic Neoplasms* / genetics

Substances

Circulating Tumor DNA
Biomarkers, Tumor